glp 1 drugs and addiction GLP-1 receptor agonists show promise in treating substance use disorders GLP-1 drugs transform lives of
Description
Liraglutide, which has been approved for reducing the risk of T2MD, has also been found to reduce the risk of major cardiovascular events in adults with established CVDs ( Table 1 Classification of GLP-1RAs
doi: 10.3122/jabfm.2015.01.140181
By improving glycemic control, promoting weight loss, and potentially reducing cardiovascular risk, GLP-1 therapy may indirectly support cognitive health through optimization of metabolic and vascular parameters
Small Molecule Glucagon Receptor Antagonists: An Updated Patent Review (2015-2019)
